Digital Breast Tomosynthesis Sales

Digital Breast Tomosynthesis Sales Market Outlook

As of 2023, the global Digital Breast Tomosynthesis (DBT) market is valued at approximately USD 3.6 billion, with a projected compound annual growth rate (CAGR) of 7.8% from 2025 to 2035. The increasing prevalence of breast cancer, coupled with a growing emphasis on early detection and diagnosis, is significantly propelling the market forward. Furthermore, advancements in imaging technology and the rising adoption of personalized medicine are key factors contributing to market growth. Enhanced diagnostic capabilities that DBT systems provide over traditional mammography are garnering more attention from healthcare facilities, ensuring a more accurate assessment of breast tissue. Additionally, government initiatives focused on breast cancer awareness and screening programs are further stimulating the demand for DBT solutions.

Growth Factor of the Market

The growth of the Digital Breast Tomosynthesis market can be attributed to a multitude of factors that enhance its appeal to healthcare providers. Firstly, the technology offers improved imaging accuracy, enabling the detection of small tumors that may be missed by traditional 2D mammography, hence, driving the demand among hospitals and diagnostic centers. Additionally, the increasing incidence of breast cancer globally has raised awareness about the importance of regular screening, further boosting the adoption of advanced imaging technologies. Innovations in DBT technology, such as integration with artificial intelligence to improve image interpretation, have also played a vital role in enhancing the efficiency and accuracy of diagnostic processes. Furthermore, increased funding for breast cancer research and diagnostic projects has stimulated investment in advanced imaging solutions. As healthcare providers aim to enhance patient outcomes through precise and early detection, the adoption of DBT systems is expected to grow significantly in the coming years.

Key Highlights of the Market

• The market is projected to witness a CAGR of 7.8% from 2025 to 2035.
• North America holds the largest market share, driven by advanced healthcare infrastructure and high awareness of breast cancer.
• Technological advancements, including artificial intelligence integration, are revolutionizing diagnostic capabilities.
• Hospitals remain the largest end-user segment, owing to the high volume of screening procedures performed.
• Increasing government initiatives for breast cancer awareness are fueling market demand.

By Product Type

1-view DBT Systems:

The 1-view DBT systems represent the simplest form of digital breast tomosynthesis technology. These systems are designed to capture a single set of images from various angles, providing a comprehensive view of breast tissue. The 1-view systems have gained traction due to their cost-effectiveness and ease of use, making them particularly appealing to smaller diagnostic imaging centers and clinics. These systems allow for quick screening processes without cumbersome setups, thus catering to the growing demand for efficient breast cancer screening solutions. The simplicity of operation and the ability to quickly interpret images contribute to their continued adoption in the market, especially in settings where budget constraints are a significant consideration.

2-view DBT Systems:

The 2-view DBT systems enhance the capabilities of the 1-view systems by capturing images from two distinct angles, allowing for a more detailed examination of the breast tissue. This additional perspective significantly improves the accuracy of detecting abnormalities, thereby increasing the confidence of healthcare professionals in their diagnostic capabilities. The 2-view systems are particularly popular in hospitals and large diagnostic centers where higher volumes of screenings are performed. The ongoing advancements in imaging technologies are being integrated into these systems, making them more efficient and user-friendly. As healthcare providers strive for greater precision in their diagnostic processes, the 2-view DBT systems are expected to witness steady growth in adoption rates.

3-view DBT Systems:

The 3-view DBT systems take diagnostic imaging a step further by providing three-dimensional views of breast tissues, which improves the detection rates of small tumors and calcifications. These systems are equipped with advanced algorithms that help in better distinguishing between benign and malignant lesions. Hospitals are increasingly adopting 3-view systems due to their ability to reduce false positives and unnecessary biopsies, thus improving patient experiences and outcomes. The added investment in 3-view technology is justified by the enhanced accuracy and reliability in diagnosis, which supports the growing number of women seeking breast cancer screenings. As awareness about breast health continues to rise, the demand for 3-view DBT systems is projected to increase considerably.

4-view DBT Systems:

4-view DBT systems provide an even more comprehensive assessment of breast tissues by capturing images from four different angles. This multi-angle approach results in superior imaging that aids radiologists in making informed decisions regarding further diagnostic steps. The enhanced depth perception and clarity of images lead to improved detection rates, making these systems a valuable tool in breast cancer diagnostics. High-performance imaging and reduced likelihood of overlapping densities contribute to the growing preference for 4-view systems among hospitals and larger institutions. As technology continues to evolve, the integration of artificial intelligence with these systems is anticipated to further improve diagnostic accuracy and operational efficiencies.

5-view DBT Systems:

The 5-view DBT systems represent the pinnacle of digital breast tomosynthesis technology by capturing five distinct images from various angles. This level of detail allows for unparalleled clarity in the visualization of breast tissues, making it easier for healthcare providers to detect subtle abnormalities. Despite being the most advanced and potentially costly option among the product types, the comprehensive imaging capabilities of 5-view systems justify their use in high-volume screening centers and specialized breast clinics. As the healthcare landscape shifts towards precision medicine and personalized healthcare solutions, the adoption of 5-view DBT systems is expected to accelerate, catering to the need for improved diagnostic tools in breast cancer detection.

By Application

Hospitals:

Hospitals are the dominant application segment for Digital Breast Tomosynthesis, driven by the high volume of screening and diagnostic imaging procedures performed. The infrastructure and resources available in hospitals enable them to invest in advanced imaging technologies like DBT systems, ensuring accurate diagnoses and patient care. With the increasing incidence of breast cancer globally, hospitals are increasingly prioritizing the implementation of DBT to enhance their screening programs. The ability to provide comprehensive diagnostic services within the hospital setting not only improves patient outcomes but also helps in establishing a reputation as a leading healthcare facility. As more hospitals recognize the value of early detection in improving survival rates, the adoption of DBT technology is anticipated to grow significantly.

Diagnostic Imaging Centers:

Diagnostic imaging centers play a crucial role in breast cancer detection and have increasingly adopted Digital Breast Tomosynthesis to improve their diagnostic capabilities. These centers specialize in imaging technologies and are often equipped with the latest advancements in DBT systems, allowing them to provide accurate and timely diagnoses of breast conditions. As patient awareness regarding breast health continues to grow, diagnostic imaging centers are experiencing an uptick in demand for breast screening services. Furthermore, the increasing collaboration between imaging centers and hospitals enhances the overall patient experience by providing convenient access to advanced diagnostic technologies. The growing focus on early detection and personalized healthcare is expected to drive the proliferation of DBT technology in these centers.

Research Institutes:

Research institutes are instrumental in advancing the field of breast cancer diagnostics through ongoing studies and clinical trials involving Digital Breast Tomosynthesis. These institutions utilize advanced imaging technologies to explore new methodologies and improve existing diagnostic practices, making significant contributions towards understanding breast cancer detection and treatment. The collaboration between research institutes and healthcare facilities is critical for developing innovative imaging solutions that can be translated into clinical practice. As the demand for evidence-based practices grows, research institutes will continue to leverage DBT technology to drive breakthroughs in breast cancer diagnostics and treatment strategies, further solidifying the importance of this segment in the market.

Others:

The 'Others' segment includes various applications of Digital Breast Tomosynthesis in settings such as mobile clinics, community health initiatives, and telemedicine platforms. With the rising need for accessible breast cancer screening services, these alternative applications are gaining traction. Mobile clinics, for instance, utilize DBT technology to reach underserved populations, ensuring that women in remote areas can access critical diagnostic services. Similarly, telemedicine platforms are integrating DBT into their offerings to provide remote consultations and second opinions for patients. As these non-traditional channels continue to expand, they will play a vital role in increasing the overall penetration of DBT solutions in the market, catering to diverse patient needs.

By Distribution Channel

Direct Sales:

Direct sales remain a significant distribution channel for Digital Breast Tomosynthesis systems, allowing manufacturers to establish direct relationships with healthcare providers. This approach enables companies to provide tailored solutions based on the specific requirements of medical facilities, offering comprehensive support and training during the implementation of DBT systems. The personal interaction in direct sales often results in better customer satisfaction and loyalty, establishing long-term partnerships between manufacturers and healthcare institutions. Additionally, direct sales facilitate prompt feedback and improvement in product offerings based on user experience, ensuring that the demand for advanced DBT technology continues to grow. As hospitals and imaging centers seek to upgrade their diagnostic capabilities, the direct sales model is likely to dominate the distribution landscape.

Distributor Sales:

Distributor sales serve as an important channel for reaching a broader audience, particularly in regions where direct sales may not be feasible. Distributors often have established networks within the healthcare industry, enabling them to effectively market and supply Digital Breast Tomosynthesis systems to various medical facilities, including smaller clinics and diagnostic centers. This channel allows manufacturers to leverage the expertise of distributors in navigating local market dynamics, ensuring that DBT products are available to a wider range of healthcare providers. While distributor sales may involve additional intermediaries, they play a critical role in increasing the accessibility of DBT technology to regions that may otherwise lack advanced diagnostic solutions. The reliance on distributor sales is expected to grow as the demand for DBT continues to rise across different market segments.

By Technology

3D Tomosynthesis:

3D Tomosynthesis is the cornerstone of Digital Breast Tomosynthesis technology, providing highly detailed three-dimensional images of breast tissues. This technology allows radiologists to view breast structures in layers, significantly enhancing the detection of abnormalities that may be obscured in traditional 2D mammograms. The precision offered by 3D imaging reduces the likelihood of false positives and unnecessary biopsies, which is crucial for patient management and care. As healthcare providers continue to embrace advanced imaging solutions to improve diagnostic accuracy, 3D tomosynthesis is expected to dominate the technological landscape within the DBT market. The growing body of clinical evidence supporting the efficacy of 3D imaging in breast cancer detection is driving its adoption across hospitals and diagnostic centers worldwide.

C-View 2D Imaging:

C-View 2D Imaging technology enables the generation of high-quality 2D images from 3D tomosynthesis datasets, providing radiologists with the benefit of both imaging perspectives. This technology simplifies the reading process for healthcare professionals while maintaining the diagnostic quality of mammography. By integrating C-View with 3D tomosynthesis, facilities can enhance workflow efficiency and reduce patient exposure to radiation during screenings. The combination of these imaging modalities helps radiologists confirm findings from the 3D images and make more informed decisions regarding patient care. The versatility and effectiveness of C-View 2D Imaging technology are contributing to its growing presence in the DBT market, as healthcare professionals seek innovative solutions to improve diagnostic accuracy and patient experiences.

Synthetic 2D Imaging:

Synthetic 2D Imaging is a cutting-edge technology that generates 2D images using advanced algorithms from the 3D tomosynthesis data set, eliminating the need for an additional 2D mammogram. This innovative approach reduces overall radiation exposure, as patients can experience a comprehensive imaging session without undergoing multiple procedures. The synthetic images maintain a level of diagnostic quality comparable to traditional 2D mammograms, making them a preferred choice among radiologists. The rising awareness regarding patient safety and radiation exposure is driving the adoption of synthetic 2D imaging in healthcare facilities, further propelling its growth within the Digital Breast Tomosynthesis market as radiologists aim to enhance their diagnostic practices.

Contrast-enhanced Mammography:

Contrast-enhanced mammography is an advanced imaging technique that combines traditional mammography with contrast agents, allowing for better visualization of blood flow and tissue perfusion in breast lesions. This technology is particularly beneficial for detecting and characterizing tumors, providing radiologists with critical information to inform treatment decisions. The growing body of clinical research supporting the efficacy of contrast-enhanced mammography is driving its adoption in diagnostic settings. By integrating contrast-enhanced techniques with DBT systems, healthcare providers can achieve even greater accuracy in diagnosing breast abnormalities. As the demand for comprehensive imaging solutions continues to rise, contrast-enhanced mammography is anticipated to gain traction within the Digital Breast Tomosynthesis market, offering enhanced diagnostic capabilities.

By Region

Regional analysis indicates that North America leads the Digital Breast Tomosynthesis market, holding a significant share due to the presence of advanced healthcare infrastructure and high levels of awareness about breast cancer screening. The region is projected to maintain a CAGR of 8.2% from 2025 to 2035, as technological innovations and increasing investments in healthcare continue to drive demand. Hospitals and diagnostic imaging centers in North America are actively adopting the latest DBT systems, contributing to the rapid growth of the market. The emphasis on early detection and increased funding for breast cancer research further solidify North America's position as a leader in the Digital Breast Tomosynthesis market.

Europe stands as the second-largest market for Digital Breast Tomosynthesis, driven by government initiatives promoting breast cancer screening and the increasing adoption of advanced imaging technologies among healthcare providers. The European market is expected to grow steadily, particularly in countries like Germany and the UK, where significant emphasis is placed on improving patient outcomes through innovative diagnostic solutions. Additionally, the Asia Pacific region is witnessing rapid growth in the DBT market, attributed to the increasing incidence of breast cancer and the rising healthcare expenditure in countries such as China and India. The increased awareness of breast health and the push for advanced diagnostic capabilities are expected to propel the Asia Pacific market during the forecast period.

Opportunities

The Digital Breast Tomosynthesis market offers numerous opportunities for growth, particularly in underserved regions where access to advanced imaging technologies is limited. As global awareness of breast cancer screening increases, there is a pressing need for healthcare facilities to adopt DBT systems to cater to the rising demand for accurate diagnostics. Manufacturers can capitalize on this opportunity by establishing partnerships with healthcare providers in developing countries to implement DBT technology, thus expanding their market reach. Additionally, the integration of telemedicine and remote diagnostics presents a significant opportunity for the utilization of DBT in heightened patient access to screening services. As telehealth continues to evolve, the ability to conduct remote consultations and second opinions using DBT technology can greatly enhance patient outcomes and increase the overall efficiency of breast cancer management.

Furthermore, the ongoing advancements in imaging technology, including the integration of artificial intelligence in Digital Breast Tomosynthesis, present additional opportunities for market players. AI-driven solutions can enhance image interpretation, reduce the workload on radiologists, and improve diagnostic accuracy. By leveraging AI technology, manufacturers can significantly improve the performance of DBT systems, positioning themselves at the forefront of innovation in breast cancer diagnostics. Additionally, research institutions and healthcare organizations are increasingly investing in studies evaluating the effectiveness of DBT technology, which provides an opportunity for manufacturers to collaborate on clinical studies and gain valuable insights to further refine their offerings. As the landscape of breast cancer detection continues to evolve, the opportunities for growth and expansion in the Digital Breast Tomosynthesis market remain extensive.

Threats

Despite the growth potential within the Digital Breast Tomosynthesis market, several threats may hinder its progress. One of the primary concerns is the high cost of DBT systems, which may deter smaller healthcare providers and clinics from adopting this advanced technology. The initial investment required for purchasing and maintaining DBT equipment can be significant, and budget constraints faced by many institutions may limit their ability to implement these systems. Additionally, the ongoing economic challenges in various regions may lead to reduced healthcare funding, further impeding the adoption of innovative imaging technologies. Furthermore, reimbursement policies for DBT procedures can be inconsistent, creating uncertainty for healthcare providers regarding the financial viability of investing in DBT systems. This uncertainty may discourage facilities from upgrading their imaging technologies, thereby affecting market growth.

Another threat to the Digital Breast Tomosynthesis market is the potential for competition from alternative breast imaging technologies. As research continues to advance, new methodologies and imaging techniques may emerge that challenge the dominance of DBT systems. These alternative technologies may offer unique advantages, such as reduced radiation exposure or improved diagnostic capabilities, posing a competitive threat to established DBT solutions. Additionally, the rapid pace of technological innovation necessitates continuous investment in research and development, further straining resources for manufacturers. Ensuring that DBT systems remain at the forefront of imaging technology is crucial for maintaining market share, and the inability to keep pace with advancements could result in diminished competitiveness. As the landscape evolves, these threats will require careful consideration from market participants.

Competitor Outlook

• Hologic, Inc.
• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Fujifilm Holdings Corporation
• Canon Medical Systems
• Agfa-Gevaert Group
• Konica Minolta, Inc.
• Carestream Health, Inc.
• Leica Biosystems
• Hitachi Medical Corporation
• Medtronic plc
• Radiology Partners
• IQVIA Holdings Inc.
• Varian Medical Systems, Inc.

The competitive landscape of the Digital Breast Tomosynthesis market is characterized by the presence of several key players that are constantly innovating and enhancing their product offerings. Hologic, Inc. is a leading player known for its advanced 3D mammography systems, which have revolutionized breast cancer screening and diagnostics. The company has established a strong market presence by investing in research and development to improve imaging technology and patient outcomes. Hologic's commitment to innovation and quality has positioned it as a trusted provider in the field of breast health. The company also focuses on expanding its global footprint, collaborating with healthcare providers and institutions to promote the adoption of its DBT solutions.

GE Healthcare is another major competitor that offers comprehensive imaging solutions, including advanced Digital Breast Tomosynthesis systems. With a focus on innovation and technology integration, GE Healthcare has developed DBT systems that enhance diagnostic accuracy and workflow efficiency. The company's commitment to research and development allows it to stay ahead in the competitive landscape, as they continuously improve their imaging technologies and address the evolving needs of healthcare providers. Moreover, GE Healthcare's extensive distribution network ensures that its DBT products are accessible to various healthcare settings, from hospitals to outpatient clinics, thereby solidifying its position in the market.

Siemens Healthineers stands out for its commitment to integrating cutting-edge technology into its Digital Breast Tomosynthesis offerings. The company's innovative imaging solutions leverage advanced algorithms and artificial intelligence to enhance image interpretation, providing radiologists with powerful diagnostic tools. Siemens Healthineers prioritizes collaborations and partnerships with healthcare institutions to ensure that their products meet the demands of modern breast cancer screening. The company has made significant investments in clinical research to validate its technologies, further establishing its reputation as a leader in the field of imaging. As the market for Digital Breast Tomosynthesis continues to expand, Siemens Healthineers is well-positioned to maintain its competitive edge through ongoing innovation and strategic partnerships.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GE Healthcare
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Leica Biosystems
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Agfa-Gevaert Group
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Philips Healthcare
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Radiology Partners
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 IQVIA Holdings Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Konica Minolta, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Canon Medical Systems
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Carestream Health, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hitachi Medical Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Varian Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Fujifilm Holdings Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Digital Breast Tomosynthesis Sales Market, By Technology
    • 6.1.1 3D Tomosynthesis
    • 6.1.2 C-View 2D Imaging
    • 6.1.3 Synthetic 2D Imaging
    • 6.1.4 Contrast-enhanced Mammography
  • 6.2 Digital Breast Tomosynthesis Sales Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Imaging Centers
    • 6.2.3 Research Institutes
    • 6.2.4 Others
  • 6.3 Digital Breast Tomosynthesis Sales Market, By Product Type
    • 6.3.1 1-view DBT Systems
    • 6.3.2 2-view DBT Systems
    • 6.3.3 3-view DBT Systems
    • 6.3.4 4-view DBT Systems
    • 6.3.5 5-view DBT Systems
  • 6.4 Digital Breast Tomosynthesis Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Digital Breast Tomosynthesis Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Digital Breast Tomosynthesis Sales market is categorized based on

By Product Type

• 1-view DBT Systems
• 2-view DBT Systems
• 3-view DBT Systems
• 4-view DBT Systems
• 5-view DBT Systems

By Application

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes
• Others

By Distribution Channel

• Direct Sales
• Distributor Sales

By Technology

• 3D Tomosynthesis
• C-View 2D Imaging
• Synthetic 2D Imaging
• Contrast-enhanced Mammography

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hologic, Inc.
• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Fujifilm Holdings Corporation
• Canon Medical Systems
• Agfa-Gevaert Group
• Konica Minolta, Inc.
• Carestream Health, Inc.
• Leica Biosystems
• Hitachi Medical Corporation
• Medtronic plc
• Radiology Partners
• IQVIA Holdings Inc.
• Varian Medical Systems, Inc.